Condition (MeSH)
Multiple Endocrine Neoplasia Type 2b
ClinicalTrials.gov lists 5 trials for Multiple Endocrine Neoplasia Type 2b or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 5 trials are tagged with Multiple Endocrine Neoplasia Type 2b itself; the rest are tagged with a narrower condition beneath it.
When did Multiple Endocrine Neoplasia Type 2b trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2018 | 1 |
| 2017 | 1 |
| 2010 | 1 |
| 2007 | 1 |
| 2006 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 5 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Multiple Endocrine Neoplasia Type 2b trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Observational | 2 |
How many Multiple Endocrine Neoplasia Type 2b trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 2 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Multiple Endocrine Neoplasia Type 2b trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
Which serious adverse events do Multiple Endocrine Neoplasia Type 2b trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| AST, SGOT(serum glutamic oxaloacetic transaminase) | 1 | 1 |
| Anorexia | 1 | 1 |
| Carbon monoxide diffusion capacity (DL(co)) | 1 | 1 |
| Cardiac ischemia/infarction | 1 | 1 |
| Dehydration | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Multiple Endocrine Neoplasia Type 2b? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Fracture Risk in Pediatric Patients With MEN2B. | The Journal of clinical endocrinology and metabolism | 2022 | Yes |
| Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient. | The Journal of clinical endocrinology and metabolism | 2014 | Yes |
| Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2013 | Yes |
| Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. | Nature | 2012 | Yes |
| ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. | Cancer research | 2005 | Yes |
Showing 5 of 7 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Multiple endocrine neoplasia type 2B | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Multiple endocrine neoplasia type 2B | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Multiple endocrine neoplasia type 2B | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Multiple endocrine neoplasia type 2B | 247709 | Exact | Orphadata Science knowledge files, Product 1 |
| Multiple endocrine neoplasia type 2B | 247709 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.